During the Trading Day
| 43.76 |  +0.46 / +1.06% |
Data as of 4:01pm ET | Day’s Change | |
| 43.70 |  -0.061 / -0.14% |
| Volume: 60,000 |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $71.1B |
Company Description
Bristol-Myers Squibb Co. is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. Its pharmaceutical products include chemically-synthesized drugs, or small molecules, and an increasing portion of products produced from biological processes called biologics. The company's biopharmaceutical research and development efforts in the affective (psychiatric) disorders, Alzheimer's/dementia, cardiovascular, diabetes, hepatitis, HIV/Acquired Immunodeficiency Syndrome (AIDS), oncology, immunologic disorders and fibrotic disease areas. Bristol-Myers Squibb was founded in August 1933 and is headquartered in New York, NY.
Employees
Shareholders
| Other institutional | 34.96% |
| Mutual fund holders | 34.07% |
| Individual stakeholders | 0.35% |
Top Executives
| Lamberto Andreotti | Chief Executive Officer & Director |
| Charles A. Bancroft, MBA, CPA | Chief Financial Officer & Executive Vice President |
| Francis M. Cuss, MD | Senior Vice President-Research & Development |
| Brian Daniels, MD | SVP-Global Development & Medical Affairs |
| Elliott Sigal, MD, PhD | Director, Chief Scientific Officer & Executive VP |
.
